AHA 2018: AKCEA-APO(a)-LRx

Published: 21 Nov 2018

  • Views:

    Views Icon 257
  • Likes:

    Heart Icon 0


Prof Sotirios Tsimikas (University of California, San Diego, US) discusses the safety and efficacy of AKCEA-APO(a)-LRx to lower lipoprotein(a) levels in patients with established cardiovascular disease: A phase 2 dose-ranging trial.


Filmed by Radcliffe Cardiology on site at AHA 2018.